Advanced BioPhotonics, Inc. (fka ABPH)

[ollinbg]

Nothing official yet, that´s right. But there could be something true in these rumors. There was a presentation of study results in July last year. Those results of abph´s technology are looking good.
So in my opinion they continued working on the BioScanIR. Maybe there was a potential investor at a presentation that wants to bring this stuff to market now.

Link to the presentation:You can find it, if You type in 1801 at "Poster Number" on this page: http://www.aad.org/forms/ePosterPresentations/Default.aspx

The Presentation-Link:
http://www.aad.org/meetings/summer/abstracts/_doc/Melanoma%20and%20Pigmented%20Lesions.pdf

The study was sponsored by ABPH! (see at the end)

Melanoma and Pigmented Lesions

P1801
Dynamic infrared imaging (DIRI®) of pigmented lesions of the skin: A pilot study of a thermal and vascular imaging modality to distinguish malignant from benign lesions
Caroline C. Kim, MD, Pigmented Lesion Clinic and Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; Erika Summers, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; John Mullen, MD, Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; Maria Laura Gomez, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Dynamic Infrared Imaging (DIRI) is a noninvasive imaging technique that passively records natural Infrared Radiation (IR) emitted from living tissues that has been shown to be able to detect minute temperature changes (0.006 degrees Celsius) and vasomotor changes to a depth of ~ 200 micrometers. We hypothesized that DIRI could detect such tissue surface changes induced by a cutaneous malignancy as compared to the surrounding normal skin. A pilot study was conducted examining twenty patients from our Cutaneous Oncology and Pigmented Lesion Clinics with suspicious skin lesions that warranted biopsy to assess the utility of DIRI in skin lesions. Suspicious skin lesions were scanned with DIRI then biopsied, and DIRI results were compared to the histologic diagnoses. The investigators were blinded throughout the study and all scans were analyzed by Advanced BioPhotonics, Inc. A total of 24 skin lesions were analyzed including 4 melanomas (1 invasive, 1 melanoma in-situ, 2 metastatic), 1 squamous cell in-situ (SCCIS), and 19 benign skin lesions. DIRI correctly identified 4 out of 4 melanomas as malignant, and 15 out of 19 benign lesions as benign, while there were 4 false positive results (benign and atypical nevi) and one false negative result (SCCIS). For all cancers, it had a diagnostic sensitivity of 80 % (95% confidence interval [CI]: 28-100%), and a specificity of 78.9% (95% CI: 54-94%). For melanoma detection, however, it had a sensitivity of 100% (95% CI: 40-100%) and specificity of 80% (95% CI: 56-94%). It is notable that DIRI correctly identified the melanoma in-situ as having an altered thermal and tissue perfusion pattern rendering the malignant interpretation, perhaps suggesting that underlying vasomotor changes are already evident at this early stage of disease. In contrast, other skin tumors such as SCCIS may not have such changes. Scanning technique is being reevaluated to assess the false positive scans, given the extreme sensitivity of the instrument to temperature shifts. In summary, this is the first study using a thermal and vascular imaging modality in the investigation of cutaneous melanoma. The results, though preliminary and from a small sample, warrant further investigation with this novel imaging technique in the screening of pigmented skin lesions for cutaneous melanoma.

Commercial Support: 40% of research costs sponsored by Advanced BioPhotonics, Inc.